Published on 3 Feb 2025 on Investing.com
L'Oreal sells its €3 billion stake in Sanofi
Start tracking your investments with Statfolio
CRSP beat on earnings in three of the trailing four quarters and missed the mark in the other,...
Sanofi is not the only big pharma company targeting a share buyback campaign. On the back of boom...
(Bloomberg) -- Cosmetics giant L’Oreal SA is selling a €3 billion ($3.1 billion) stake in Sanofi...
The company’s sales and earnings growth outlook for 2025 seems quite optimistic, with expectation...
Sanofi (EPA:SASY) (NASDAQ:SNY) announced on Thursday that it plans to repurchase €5 billion ($5.2...
(Bloomberg) -- Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits...
The Sarclisa combination therapy was approved for a similar indication by the FDA in September, a...
Sanofi (SNY) has received EU regulatory approval for its drug Sarclisa for the treatment of newly...
The U.S. Food and Drug Administration (FDA) issued a warning letter to Sanofi SA’s SNY Genzyme Co...